ASH 2022 | EPCORE NHL-1 subgroup analyses: epcoritamab monotherapy in patients with R/R LBCL

In a nutshell, this is just a follow-up from the initial presentation that was given at EHA. It basically looks at a subset analysis and breaks it down into certain cohorts, looking at different patient characteristics. What I will say is that most patients had a good response to epcoritamab. What we did see was a slight decrease in overall and complete response for the patients who happened to be CAR-T refractory. But other than that, it was pretty much consistent across the board based on looking at age, patient fitness and number of lines of therapy.

Additionally, those who obtained a CR had very durable CRs in this situation and maintained. A significant number of those patients were still in remission at the data cutoff. And it did seem to be a correlation between those who were minimal residual disease undetectable or did not have any evidence of disease with the molecular testing. There was a high correlation between that and complete responses that we saw with radiographic imaging. Suggests in epco, the patients who do respond and who actually obtain a complete remission, there is some durability of those remissions. And potentially we will hopefully see a plateau in these patients. Thus allowing us to say that maybe these patients will get responses somewhat close to what we can see with CAR-T.

The next step will be obviously trying to determine those patients who are on remission and remain in remission, if we can actually stop epcoritamab at some point. As of right now, it is a continual treatment until progression or intolerance.